Login
$GERN
$0.97 +$0.03 (2.77%) After hours

Company Executives

Management Team

From the 10-K annual report
Officer Age In this role 2025 pay Source
Harout Semerjian Also a director
President, Chief Executive Officer and Board member
55 Since 2025
1 year
$10,221,755
Michelle Robertson
Executive Vice President, Finance, Chief Financial Officer and Treasurer
59 Not stated $2,250,082
Ahmed ElNawawi
Executive Vice President, Chief Commercial Officer
45 Not stated $2,881,334
Timothy Williams
EVP and Chief Legal Officer
Title from the Form 4 dated Apr 13, 2026
Not stated Not stated Not reported
Joseph Eid
Executive Vice President, Research and Development
58 Not stated $1,001,052

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
9
serving now
Independent
8 of 9
stated in the proxy
Average tenure
6.1 years
from year joined
CEO also chairs the board
No
Elizabeth G. O’Farrell
Director Age On board Independent Committees Other public boards Pay Source
Elizabeth G. O’Farrell
61 2019
7 years
Independent
Audit Committee · Chair
LENSAR, Inc., Genmab A/S, SpyGlass Pharma, Inc. Not stated
Harout Semerjian
55 2025
1 year
Not independent None stated None stated Paid as CEO
Susan M. Molineaux
72 2012
14 years
Independent
Compensation Committee · Chair
None stated Not stated
Patricia S. Andrews
68 2026
this year
Independent None stated Glenmark Pharmaceuticals Limited, Oncolytics Biotech Inc. Not stated
Constantine Chinoporos
59 2026
this year
Independent None stated None stated Not stated
Dawn C. Bir
55 2019
7 years
Independent
Compensation Committee
Cassava Sciences, Inc., Soleno Therapeutics, Inc. Not stated
John F. McDonald
65 2022
4 years
Independent None stated None stated Not stated
Robert J. Spiegel
76 2010
16 years
Independent None stated Ayala Pharmaceuticals, RenovoRx Not stated
V. Bryan Lawlis Leaving at the meeting
Not stated Not stated Independent None stated None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 7, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support